Clinical trial
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Recruiting now · Phase 3 · 5 countries · Registry ID NCT07321886
Recruiting nowPhase 3Interventional
What this study is about
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionObesity, Overweight
Full registry criteria
Inclusion Criteria: * Have Body Mass Index (BMI) at screening of the following: * 30 kilogram per square meter (kg/m2) OR * 27 kg/m2 with at least one of the following weight-related health conditions at screening: * high blood pressure * dyslipidemia * obstructive sleep apnea, or * heart disease * Have a stable body weight (\<5% body weight change) for 90 days prior to screening. * Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight Exclusion Criteria: * Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) * Have type 1 diabetes or type 2 diabetes * Have had within 90 days prior to screening: * heart attack * stroke * coronary artery revascularization * unstable angina, or * hospitalization due to congestive heart failure * Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure * Have taken medications or alternative remedies intended for weight loss within 90 days of screening
Treatments and study arms
Eloralintide
Drug
Administered SC
Placebo
Drug
Administered SC
Primary outcomes
Percent Change from Baseline in Body WeightBaseline, Week 64
Study locations
162 locations were listed when this page was built. The first 40 are shown.
CARDIAMET Investigaciones Médicas🇦🇷 Buenos Aires, Argentina
Study contactContact
Angela Romero ZarantePrincipal Investigator
CONEXA Investigacion Clinica S.A.🇦🇷 Buenos Aires, Argentina
Study contactContact
María SciosciaPrincipal Investigator
Cardiología Palermo🇦🇷 Buenos Aires, Argentina
Study contactContact
Paula Perez TernsPrincipal Investigator
Centro Médico Viamonte🇦🇷 Buenos Aires, Argentina
Study contactContact
Diego AizenbergPrincipal Investigator
Cicemo Srl🇦🇷 Buenos Aires, Argentina
Study contactContact
Pablo CostanzoPrincipal Investigator
Fundación Respirar🇦🇷 Buenos Aires, Argentina
Study contactContact
Marina UhrigPrincipal Investigator
Glenny Corp. S.A.🇦🇷 Buenos Aires, Argentina
Study contactContact
Martin KoretzkyPrincipal Investigator
Instituto de Investigaciones Clínicas Córdoba🇦🇷 Córdoba, Argentina
Study contactContact
Mauro PautassoPrincipal Investigator
INECO Neurociencias Oroño🇦🇷 Rosario, Argentina
Study contactContact
María CappielloPrincipal Investigator
Centro Modelo de Cardiología🇦🇷 San Miguel de Tucumán, Argentina
Study contactContact
GUILLERMO MERCAUPrincipal Investigator
Core Research Group🇦🇺 Brisbane, Australia
Study contactContact
David ColquhounPrincipal Investigator
Life Clinical Research🇦🇺 Ipswich, Australia
Study contactContact
Cameron BoothPrincipal Investigator
Paratus Clinical Research Central Coast🇦🇺 Kanwal, Australia
Ian ForsythPrincipal Investigator
University of the Sunshine Coast (UniSC) Clinical Trials - Meadowbrook🇦🇺 Meadowbrook, Australia
Ivan LimPrincipal Investigator
Momentum Sunshine🇦🇺 Melbourne, Australia
Study contactContact
King CheungPrincipal Investigator
Paratus Clinical Research - Melbourne🇦🇺 Melbourne, Australia
Kianoosh Noori SamiePrincipal Investigator
AIM Research🇦🇺 Merewether, Australia
Study contactContact
Claire MorbeyPrincipal Investigator
USC Clinical Trials Sunshine Coast🇦🇺 Sippy Downs, Australia
Robert ScottPrincipal Investigator
ANIMA Research🇧🇪 Diepenbeek, Belgium
Study contactContact
Hilde BollenPrincipal Investigator
Jessa Ziekenhuis🇧🇪 Hasselt, Belgium
Study contactContact
Guido ClaessenPrincipal Investigator
Kormont🇧🇪 Kluisbergen, Belgium
Study contactContact
Klaas VercruyssePrincipal Investigator
Gezondheidshuis De Gloed🇧🇪 Machelen, Belgium
Study contactContact
Klaas VercruyssePrincipal Investigator
Instituto de Pesquisa clinica de Campinas🇧🇷 Campinas, Brazil
Study contactContact
Sylka RodovalhoPrincipal Investigator
Private Practice - Dr.Miguel N. Hissa🇧🇷 Fortaleza, Brazil
Centro de Pesquisa Clínica de Marília - CPCLIM🇧🇷 Marília, Brazil
Study contactContact
José SgarbiPrincipal Investigator
Núcleo de Pesquisa Clínica do Rio Grande do Sul🇧🇷 Porto Alegre, Brazil
Study contactContact
Luis Henrique CananiPrincipal Investigator
IBPClin - Instituto Brasil de Pesquisa Clínica🇧🇷 Rio de Janeiro, Brazil
Study contactContact
Renata Alexandra PinheiroPrincipal Investigator
Ruschel Medicina e Pesquisa Clínica🇧🇷 Rio de Janeiro, Brazil
Study contactContact
Luiza SiffertPrincipal Investigator
CEPIC - Centro Paulista de Investigação Clínica🇧🇷 São Paulo, Brazil
Study contactContact
Breno Balabem AlvesPrincipal Investigator
CPCLIN🇧🇷 São Paulo, Brazil
CEDOES🇧🇷 Vitória, Brazil
Integral Pesquisa e Ensino🇧🇷 Votuporanga, Brazil
Aggarwal and Associates Limited🇨🇦 Brampton, Canada
Study contactContact
Naresh AggarwalPrincipal Investigator
Med Trust Research🇨🇦 Courtice, Canada
Study contactContact
Anojan KathirkamanayaganPrincipal Investigator
Dawson Clinical Research Inc.🇨🇦 Guelph, Canada
Study contactContact
Garry WallacePrincipal Investigator
The Wharton Medical Clinic Clinical Trials Inc🇨🇦 Hamilton, Canada
Study contactContact
Mateen AkhtarPrincipal Investigator